在患有慢性病的患者中,甘油三指数与肉症之间的关联
Yifen Zhang1,2, Fan Zhang1,2, Wenjian Li3,4
1Department of Endocrinology, Changzhou Third People's Hospital, Changzhou, China.
Frontiers in endocrinology
|October 6, 2025
概括
甘油三糖 (TyG) 指数与慢性脏病 (CKD) 患者的肉症风险更高有关. 这一发现突显了胰岛素耐药性在肉症发展中的作用以及CKD的预防策略.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 代谢医学是一种代谢医学.
- 老年病的医生 老年病的医生
背景情况:
- 萨科佩尼亚是慢性病 (CKD) 患者的重大并发症,导致不良健康结果.
- 甘油三糖 (TyG) 指数越来越被认为是胰岛素耐药性的标志物.
- 了解与慢性脏疾病中 Sarcopenia 相关的因素对于开发有效的干预措施至关重要.
研究的目的:
- 调查慢性病 (CKD) 患者的甘油三-葡萄糖 (TyG) 指数和肉症之间的关联.
- 探索TyG指数作为CKD中肉症的生物标志物的潜力.
- 提供关于预防和治疗慢性脏病中肉类的见解.
主要方法:
- 分析了来自两个大型队列的数据:NHANES (美国) 和一个中国队列 (2018-2023).
- 包括来自美国的827名CKD患者和来自中国的1038名CKD患者.
- 后勤回归,多变量调整和受限立方线 (RCS) 建模被用来分析TyG指数和萨科佩尼亚之间的关系.
主要成果:
- 在两个队列中,在CKD患者中,TyG指数和肉症之间发现了显著的积极关联.
- 最高的TyG指数四分位数与美国队列中 Sarcopenia 的风险增加了4.01倍 (P=0.002) 和中国队列中风险增加了3.25倍 (P<0.001).
- RCS分析证实了非线性正相关性,小组分析表明,在没有糖尿病或代谢综合征的患者中,相关性更强.
结论:
- 泰格指数可以作为一个有价值的生物标志物来评估慢性病患者的肉症风险.
- 这些发现支持胰岛素耐药性在CKD患者中萨尔科佩尼亚病变的作用.
- 需要进一步的研究来澄清底层机制,并制定有针对性的干预措施.
相关概念视频
Chronic Kidney Disease II: Clinical Manifestations
552
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
552
Chronic Kidney Disease III: Interprofessional Care
339
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
339
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
189
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
189
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
234
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
234
Hypoglycemia and Glucagon
830
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
830
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
246
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
246


